Home » Stocks » 89bio

89bio, Inc. (ETNB)

Stock Price: $24.59 USD 0.26 (1.07%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
After-hours: $24.98 +0.39 (1.59%) Oct 27, 4:17 PM

Stock Price Chart

Key Info

Market Cap 488.82M
Revenue (ttm) n/a
Net Income (ttm) -60.32M
Shares Out 19.88M
EPS (ttm) -72.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $24.59
Previous Close $24.33
Change ($) 0.26
Change (%) 1.07%
Day's Open 24.33
Day's Range 23.76 - 25.00
Day's Volume 103,907
52-Week Range 14.00 - 47.25

More Stats

Market Cap 488.82M
Enterprise Value 414.90M
Earnings Date (est) Dec 16, 2020
Ex-Dividend Date n/a
Shares Outstanding 19.88M
Float 16.07M
EPS (basic) 5.66
EPS (diluted) -72.33
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 498,532
Short Ratio 1.78
Short % of Float 3.10%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.90
Revenue n/a
Operating Income -40.18M
Net Income -60.32M
Free Cash Flow n/a
Net Cash 73.92M
Net Cash / Share 3.72
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -50.78%
ROE -136.33%
ROIC 859.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(140.95% upside)
Current: $24.59
Target: 59.25
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-26.64-15.16
Net Income-57.42-16.18
Shares Outstanding2.340.44
Earnings Per Share-24.49-36.45
Operating Cash Flow-25.46-12.47
Capital Expenditures-0.14-0.04
Free Cash Flow-25.60-12.51
Cash & Equivalents93.3611.26
Net Cash / Debt93.3611.26
Book Value89.94-16.06
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name 89bio, Inc.
Country United States
Employees 24
CEO Rohan Palekar

Stock Information

Ticker Symbol ETNB
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ETNB
IPO Date November 11, 2019


89bio, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.